HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE

Clinical trials for HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE explained in plain language.

Never miss a new study

Get alerted when new HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE trials appear

Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

New hope for Tough-to-Treat breast cancer after standard therapy fails

Disease control Terminated

This study tested whether combining the drug repotrectinib with or without fulvestrant could help control metastatic lobular breast cancer in people whose disease progressed after standard hormone therapy. The trial enrolled 6 participants with hormone-positive, HER2-negative met…

Matched conditions: HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Apr 04, 2026 06:50 UTC

HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE

Get alerted when new HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE trials appear

New hope for Tough-to-Treat breast cancer after standard therapy fails